Pfizer Inc. (PFE) Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences, Inc.
1/5/2012 10:56:23 AM
More...
|
Catalyst Biosciences, Inc. Receives $4 Million Milestone Payment from Pfizer Inc. (PFE) for Progress in Lead Hemostasis Program
12/16/2010 6:42:47 AM
More...
|
Catalyst Biosciences, Inc. Appoints William J. Dawson Chief Financial Officer
3/2/2010 11:42:17 AM
More...
|
Catalyst Biosciences, Inc. Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics; Catalyst Will Receive Milestone up to $195 Million
7/7/2009 7:20:08 AM
More...
|
Wyeth (WYE), Catalyst Biosciences, Inc. Sign Deal Worth Potentially $500 Million
6/30/2009 7:03:35 AM
More...
|
Catalyst Biosciences, Inc. Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
3/24/2009 12:12:44 PM
More...
|
Catalyst Biosciences, Inc. Raises $40 Million in Series C Financing
12/3/2008 6:42:53 AM
More...
|
Catalyst Biosciences, Inc. Appoints Dr. Todd Lorenz Chief Medical Officer
10/28/2008 8:14:08 AM
More...
|
Catalyst Biosciences, Inc. Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
5/7/2008 7:24:59 AM
More...
|
Catalyst Biosciences, Inc. and Centocor Research And Development, Inc. Form Collaboration to Discover and Develop Engineered Protease Therapeutics
1/7/2008 6:54:05 AM
More...
|
|